newsfilter
← Latest News
Business Wire·

Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology

BANNOCKBURN, Ill. & DURHAM, N.C.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, the genome editing company, today announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers.